StemCyte, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Covina CA United States (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2011
NCT01471613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

StemCyte, Inc. | StemCyte Taiwan Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Ischemia (Phase 1)

Cerebral Infarction (Phase 1)

Ischemia (Phase 1)

Spinal Cord Injuries (Phase 2)

Stroke (Phase 1)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4